Steris Plc (STE) Q2 2025 (Ended Sept 30, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024 (Q2 of Fiscal 2025). Steris Plc is a global provider of infection prevention products and services, operating through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in May 2024 and is reported as discontinued operations. The company is a large accelerated filer incorporated in Ireland.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $1,328.9M | $1,238.2M | $2,608.4M | $2,421.6M |
| Gross Profit | $578.8M | $546.2M | $1,151.2M | $1,075.2M |
| Gross Margin | 43.6% | 44.1% | 44.1% | 44.4% |
| Operating Income | $219.7M | $191.6M | $405.2M | $389.3M |
| Net Income (Attributable to Shareholders) | $150.0M | $115.3M | $295.4M | $238.9M |
| Diluted EPS | $1.51 | $1.16 | $2.98 | $2.41 |
| Operating Cash Flow (YTD) | $554.5M (vs $427.2M YTD 2024) | |||
| Free Cash Flow (YTD) | $344.5M (vs $284.7M YTD 2024) | |||
| Total Debt | $2.24B (Sept 30, 2024) vs $3.21B (Mar 31, 2024) | |||
| Cash & Equivalents | $172.2M (Sept 30, 2024) | |||
| Debt-to-Total Capital | 25.3% (Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 7.3% QoQ and 7.7% YTD, driven by organic volume growth (particularly in Healthcare consumables and services) and pricing. The BD acquisition contributed to volume in the Healthcare segment.
- Margin Compression: Gross margin decreased slightly (43.6% vs 44.1% in Q2) due to unfavorable labor/overhead costs, productivity impacts, and restructuring charges, partially offset by pricing benefits.
- Restructuring: The company incurred $2.8M in restructuring expenses in Q2 and $30.9M YTD related to a plan announced in May 2024, targeting ~$25M in annual savings.
- Debt Reduction: Total debt decreased significantly from $3.21B to $2.24B following the sale of the Dental segment. Proceeds were used to pay down term loans and the revolving credit facility.
- Divestitures: The Dental segment was sold for $787.5M (closed May 31, 2024). The Controlled Environment Certification Services (CECS) business was sold for $41.9M net proceeds.
Guidance, Outlook, and Risks
- Outlook: Management expects the restructuring plan to be substantially complete by the end of Fiscal 2025, with annual operating income improvements of approximately $25M realized primarily in Fiscal 2026 and beyond.
- Capital Allocation: The company continues to return capital to shareholders, having repurchased $100M of shares YTD and paid $1.09 per share in dividends YTD. $400M remains available under the share repurchase program.
- Risks & Contingencies:
- Legal Proceedings: Approximately 275 individual plaintiffs have filed suits alleging cancer from ethylene oxide (EO) exposure at an Illinois facility. A loss is reasonably possible, but a range cannot be estimated; the first trial is scheduled for November 2024.
- Tax Matters: The company is contesting IRS Notices of Deficiency regarding deemed dividend inclusions (potential $50M liability) but has not established reserves.
- Market Risks: Exposure to foreign currency fluctuations and commodity prices (nickel), though hedging strategies are in place.
Investor Verification Checklist
- Verify the impact of the BD acquisition on future Healthcare segment organic growth rates.
- Monitor the outcome of the November 2024 trial regarding ethylene oxide exposure litigation.
- Track the realization of the $25M annual cost savings from the restructuring plan in Fiscal 2026.
- Review the status of the IRS tax dispute regarding the $50M potential liability.
- Assess the sustainability of gross margin recovery given ongoing labor and overhead cost pressures.